Surgery Partners Faces Stock Market Challenges

On Monday, Surgery Partners saw an unfortunate dip in its stock performance, which was part of a broader downturn in the market. Investors were engaged in trading, particularly focusing on sectors like healthcare. Following the release of the latest quarterly results, the company’s stock experienced a drop of nearly 25%, even though the S&P 500 managed a modest increase of 1.5%.

In the third quarter, Surgery Partners reported revenues of $821.5 million, which is a solid year-over-year growth of almost 7%. However, when it came to net income—well, that was a different situation. It fell by 31%, landing at $16.5 million, equating to about $0.13 per share, which is not great.

This was termed a “double miss” by analysts since they were anticipating revenues closer to $821.9 million and adjusted earnings around $0.21 per share. It’s interesting how expectations can sometimes be slightly off, but this felt like more than just a minor slip.

In their earnings report, the company attributed its sales growth to robust performance in orthopedic surgeries. But there were some challenges mentioned, particularly regarding “volume and payer mix trends,” which could be a concern moving forward.

To compound these issues, Surgery Partners also fell short of its full-year earnings guidance. The company is expecting revenues for 2025 to fall between just under $3.28 billion and $3.3 billion, while analysts had hoped for slightly over $3.35 billion. That discrepancy is notable.

Management has projected earnings before interest, taxes, depreciation, and amortization (EBITDA) in the range of $535 million to $540 million, which—one would hope—offers some encouragement.

Before deciding to invest in Surgery Partners’ stock, here are some things to consider:

It appears that the analysis team from Motley Fool Stock Advisor has identified ten different stocks with promising potential returns right now. Interestingly, Surgery Partners isn’t among them. These ten picks are worth noting if you’re scouting for strong investment opportunities.

The gains from previous recommendations are striking as well—just think about the growth seen in stocks like Netflix and Nvidia if invested when they were first suggested.

Overall, the average return from the Stock Advisor program has been considerably higher than the S&P 500, highlighting some significant outperformance. It’s essential to keep a keen eye on the developments surrounding Surgery Partners as the market evolves.